DrugPatentWatch Database Preview

Details for Patent: 8,796,276

Which drugs does patent 8,796,276 protect, and when does it expire?

Patent 8,796,276 protects ARISTADA and is included in one NDA.

This patent has twenty-nine patent family members in eighteen countries.

Summary for Patent: 8,796,276

Title:	Heterocyclic compounds for the treatment of neurological and psychological disorders
Abstract:	Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed. ##STR00001##
Inventor(s):	Remenar; Julius F. (Framingham, MA), Blumberg; Laura Cook (Lincoln, MA), Zeidan; Tarek A. (Watertown, MA)
Assignee:	Alkermes Pharma Ireland Limited (Dublin, IE)
Application Number:	13/607,066
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,796,276

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-001	Oct 5, 2015		RX	Yes	No	➤ Sign Up	➤ Sign Up				TREATMENT OF SCHIZOPHRENIA	➤ Sign Up
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-002	Oct 5, 2015		RX	Yes	No	➤ Sign Up	➤ Sign Up				TREATMENT OF SCHIZOPHRENIA	➤ Sign Up
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				TREATMENT OF SCHIZOPHRENIA	➤ Sign Up
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-004	Jun 5, 2017		RX	Yes	No	➤ Sign Up	➤ Sign Up				TREATMENT OF SCHIZOPHRENIA	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 8,796,276

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
8,431,576	Heterocyclic compounds for the treatment of neurological and psychological disorders	➤ Sign Up
9,102,618	Prodrugs of NH-acidic compounds	➤ Sign Up
8,686,009	Prodrugs of NH-acidic compounds	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 8,796,276

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Japan	5733841	➤ Sign Up
Japan	2015063562	➤ Sign Up
Spain	2639065	➤ Sign Up
Croatia	P20171415	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 8,796,276

For more information try a trial or see the plans and pricing